FDA to review brentuximab

FDA accepted for review and granted Priority Review to two BLAs from Seattle Genetics Inc. (NASDAQ:SGEN) for brentuximab vedotin to treat relapsed or refractory Hodgkin's lymphoma and to treat relapse...